Asahi Kasei secures global rights to novel Alchemedicine preclinical compounds
Asahi Kasei Pharma receives worldwide exclusive rights for the research, development, manufacturing, and marketing of the active ingredients
Asahi Kasei Pharma receives worldwide exclusive rights for the research, development, manufacturing, and marketing of the active ingredients
Zydus has developed an innovative Semaglutide Injection (15 mg/3 ml) in a prefilled cartridge administered using a patient-friendly reusable pen for which the company has exclusive rights
The new solution combines Watchmaker Genomics’ high-performance NGS chemistry with Volta’s digital fluidics platform
Sodium Phosphates Injection is indicated as a source of phosphorus, for addition to large volume intravenous fluids, to prevent or correct hypophosphatemia in patients with restricted or no oral intake
Brivaracetam Oral Solution (10 mg/mL) is a prescription antiepileptic drug (anticonvulsant) used for treatment of partial-onset seizures in patients 1 month of age and older
Sugemalimab, developed using CStone’s OmniRat transgenic platform, is a fully human IgG4 monoclonal antibody designed to minimize immunogenicity and toxicity
CagriSema produced a 23% weight loss at 84 weeks, versus 25.5% for tirzepatide
The announcement follows a record-setting $1.2 million accelerated LineaDNA order
The Phase 2 trial, conducted through Starton’s Sargon Site Network, is expanding from two to six sites across the U.S.
Nadda underlined that India’s policy framework is aligned with this transformation
Subscribe To Our Newsletter & Stay Updated